ROPER TECHNOLOGIES INC ROP

Roper Technologies Inc filed a 10-Q for the quarter ending 2026-03-31 showing $2.10B of revenue, $569.6M of operating income, and $508.9M of net income attributable to the parent, with diluted earnings per share of $4.87 on 104.6M weighted average diluted shares. The same filing reports $592.1M of net cash provided by operating activities, set against just $382.9M of cash and cash equivalents on the balance sheet, a deliberately lean cash line for a company carrying $34.55B of assets.

Roper is not a single-product manufacturer but an owner of niche software and measurement businesses. The 10-Q describes 5.2% organic revenue growth led by application software serving the legal market, the project-based private sector, higher education, and property and casualty insurance. Its Technology Enabled Products segment grew 8.5% to $476.2 from $438.7 a year earlier, with 7.1% organic growth led by medical products, precision measurement, and airway management. That mix is why one quarterly invoice run can matter more than any factory.

On the balance sheet, the 10-Q lists $15.73B of liabilities against $18.82B of stockholders' equity attributable to the parent, with inventory of $144.5M and a $3.3M increase in inventories over the period, figures consistent with a software-weighted model rather than a heavy goods maker. The FY2025 10-K records $852.5M of research and development expense, the spending that keeps acquired franchises current. The 8-K dated 2026-04-23 confirms the company issued a press release on its first-quarter results for the period ended 2026-03-31.

The supplied source rail is SEC EDGAR rather than a chart route, so this file references official filings and ownership documents, not price levels or candles. The 8-K dated 2026-05-19 reports that shareholders, at the Annual Meeting, approved an amendment and an amendment and restatement of the Roper Technologies stock plan. Six Form 4 ownership filings dated 2026-05-21 sit on the EDGAR index, the routine insider statements that follow share movement among officers and directors.

What changed this cycle is incremental rather than dramatic: continued organic growth concentrated in software and medical-adjacent hardware, a freshly restated incentive plan, and quarterly cash generation that comfortably exceeds the cash held at quarter end. What the rail does not prove is forward guidance, dividend or buyback specifics, segment margin detail beyond the cited lines, or any product approval, since the scout supplied filing evidence rather than a product launch. Parsed guidance, free cash flow definitions, and segment margin tables would deepen the file next.